Methods of administering chimeric antigen receptor immunotherapy
AssigneeKite Pharma, Inc.
InventorJeffrey S. Wiezorek
Life of this patent
Estimating the term…
Abstract
The disclosure provides cells comprising CD19-directed chimeric antigen receptor (CAR) genetically modified autologous T cell immunotherapy for the treatment of, e.g., relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T cell therapy provided herein.
Claims15
A method for treating, high grade B-cell lymphoma in a patient comprising:
- administering to the patient in need thereof an axicabtagene ciloleucel suspension by intravenous infusion at a dose between about 1×106 and about 2×106 CAR-positive viable T cells per kg body weight up to a maximum dose of about 2×108 CAR-positive viable T cells,
- wherein axicabtagene ciloleucel is a CD19-directed genetically modified autologous T cell immunotherapy, comprising the patient's own T cells harvested and genetically modified ex vivo by retroviral transduction to express a chimeric antigen receptor (CAR) comprising an anti-CD19 single chain variable fragment (scFv) linked to CD28 and CD3-zeta co-stimulatory domains.
Dependencies are inferred from the claim text.